Accelerate Diagnostics

Accelerate Diagnostics, Inc. is an in vitro diagnostics company, which engages in the provision of solutions that improve patient outcomes and lower healthcare costs through the rapid diagnosis of serious infections. It also focuses on developing and commercializing innovative instrumentation for the rapid identification and antibiotic susceptibility testing of infectious pathogens. The firm's products include Accelerate Pheno and Accelerate PhenoTest. The company was founded in 1982 and is headquartered in Tucson, AZ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Accelerate Diagnostics reports Q1 losses but shows growth potential

Accelerate Diagnostics showcased growth potential with customer acquisitions, Wave program progress, and strategic partnerships, despite facing cost management challenges.
The company's focus on innovation, customer engagement, and operational efficiency positions it for market expansion and technology advancement in the diagnostics sector.
Addressing expense control, successful commercialization of new programs, and sustaining growth momentum are key focus areas for Accelerate Diagnostics to drive profitability.

Accelerate Diagnostics reports Q3 milestones amidst financial challenges

Accelerate Diagnostics demonstrated financial performance with notable milestones achieved in Q3 2024.
While facing challenges in managing cash burn and addressing analyst inquiries, the company showcased strengths in commercial progress and innovation.
Opportunities for growth and market leadership exist through leveraging recent FDA clearances and expanding into new markets.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

TUCSON, Ariz., Aug. 3, 2021 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ:AXDX) today announced that the new IVD configuration of its Accelerate PhenoTest® BC kit has been CE marked and is ready for use in Europe.

Accelerate Diagnostics Announces CE Mark and Availability in Europe of Fast Antimicrobial Susceptibility Test for Use with Existing ID Systems

Its new system marks a groundbreaking advance in the field of testing for bloodstream infections.

This In Vitro Diagnostics Company Is Poised to Capture Its Share of a Growing Market

Accelerate Diagnostics (AXDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Accelerate Diagnostics (AXDX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

TUCSON, Ariz., July 15, 2021 /PRNewswire/ -- Accelerate Diagnostics, Inc. announced today that management will host a conference call on Thursday, August 5, 2021, at 4:30 p.m.

Accelerate Diagnostics Schedules Call to Review 2nd Quarter 2021 Results

Investors were encouraged by a recent award the company received in the effort to diagnose and treat sepsis more rapidly.

Up 6% in June, Is Accelerate Diagnostics a Good Buy Now?

TUCSON, Ariz., July 7, 2021 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ: AXDX) today announced the launch of a new IVD configuration of its Accelerate PhenoTest® BC kit in the United States.

Accelerate Diagnostics Launches a Fast Antimicrobial Susceptibility Test for Use with Existing ID Systems in the United States

TUCSON, Ariz., June 30, 2021 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ:AXDX) today announced that it will have 3 data presentations from its Improving Outcomes and Antibiotic Stewardship (IOAS) Study at the European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) to be held July 9–12, 2021.

New Accelerate Pheno® Landmark Study Validates Important Clinical Benefits to Be Presented at ECCMID 2021

TUCSON, Ariz., May 19, 2021 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ: AXDX) announced today that Chief Executive Officer, Jack Phillips, and Chief Financial Officer, Steve Reichling, will present virtually at the William Blair 41st Annual Growth Stock Conference on Thursday, June 3, 2021 at 12:00 p.m.

Accelerate Diagnostics to Participate in William Blair 41st Annual Growth Stock Conference on June 3, 2021

Accelerate Diagnostics, Inc. (AXDX) CEO Jack Phillips on Q1 2021 Results - Earnings Call Transcript

TUCSON, Ariz., May 6, 2021 /PRNewswire/ -- Accelerate Diagnostics, Inc. (Nasdaq: AXDX) today announced financial results for the first quarter for the period ended March 31, 2021.

Accelerate Diagnostics Reports First Quarter 2021 Financial Results

TUCSON, Ariz., May 5, 2021 /PRNewswire/ -- Accelerate Diagnostics, Inc. (Nasdaq: AXDX) announced today that management will host a conference call on Thursday, May 6, 2021 at 4:30 p.m.

Accelerate Diagnostics to Host Call to Review First Quarter 2021 Results

Accelerate Diagnostics, Inc. (AXDX) CEO Jack Phillips on Q4 2020 Results - Earnings Call Transcript

TUCSON, Ariz., Feb. 23, 2021 /PRNewswire/ -- Accelerate Diagnostics, Inc. (Nasdaq: AXDX) today announced financial results for the fourth quarter and full year ended December 31, 2020. "We were pleased with the improvement in our go-live execution over the course of 2020, which drove a...

Accelerate Diagnostics Reports Fourth Quarter and Full-Year 2020 Financial Results

TUCSON, Ariz., Jan. 12, 2021 /PRNewswire/ -- Accelerate Diagnostics, Inc. (Nasdaq: AXDX) today announced preliminary financial results for the fourth quarter and full year ending December 31, 2020. Highlights for the fourth quarter and full-year 2020 are presented below. 2020 Fourth...

Accelerate Diagnostics Announces Preliminary Fourth Quarter and Full-Year 2020 Financial Results

Accelerate Diagnostics, Inc. (AXDX) CEO Jack Phillips on Q3 2020 Results - Earnings Call Transcript

TUCSON, Ariz., Nov. 5, 2020 /PRNewswire/ -- Accelerate Diagnostics, Inc. (Nasdaq: AXDX) today announced financial results for the third quarter ended September 30, 2020. "We achieved solid revenue growth in the third quarter, driven by continued steady utilization within our installed...

Accelerate Diagnostics Reports Third Quarter 2020 Financial Results

Will Accelerate Diagnostics (AXDX) Report Negative Earnings Next Week? What You Should Know

TUCSON, Ariz., Aug. 24, 2020 /PRNewswire/ -- Accelerate Diagnostics, Inc.

Accelerate Diagnostics Names Nedal Safwat Chief Strategy Officer

This new testing platform will speed up health checks by determining whether asymptomatic people have COVID-19 antibodies in 30 minutes.

Accelerate Diagnostics Announces Emergency Use Authorization for Covid-19 Antibody Test

TUCSON, Ariz., Aug. 18, 2020 /PRNewswire/ -- Accelerate Diagnostics, Inc.

Accelerate Diagnostics Announces FDA Emergency Use Authorization for COVID-19 Antibody Testing System

Accelerate Diagnostics (AXDX) CEO Jack Phillips on Q2 2020 Results - Earnings Call Transcript

TUCSON, Ariz., Aug. 6, 2020 /PRNewswire/ -- Accelerate Diagnostics, Inc.

Accelerate Diagnostics Reports Second Quarter 2020 Financial Results & Announces New Product Offering

Accelerate Diagnostics (AXDX) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Accelerate Diagnostics (AXDX) Moves to Strong Buy: Rationale Behind the Upgrade

Accelerate Diagnostics (AXDX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

How Accelerate Diagnostics (AXDX) Stock Stands Out in a Strong Industry

Accelerate Diagnostics, Inc. (AXDX) CEO Jack Phillips on Q1 2020 Results - Earnings Call Transcript

News for Accelerate Diagnostics Stock (AXDX)